Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of May 2025, with the report dated May 14, 2025. The document primarily addresses a corporate action involving the grant of employee warrants and an amendment to the Company's Articles of Association.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on equity compensation terms.
Material Changes
- Warrant Grant: On May 13, 2025, the Board of Directors granted 36,390 warrants to certain employees.
- Exercise Price: The exercise price is set at US $161.52 per share, based on the closing price of the American Depositary Shares (ADS) on the grant date.
- Vesting Schedule: 25% of the warrants vest on the one-year anniversary of the grant date. The remaining 75% vest monthly at a rate of 1/36th thereafter, subject to continued service.
- Articles of Association: The Company amended its Articles of Association to facilitate this grant.
- Remaining Pool: After this grant, 1,838,303 warrants remain available for future grants under the Articles of Association.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The vesting of warrants is subject to earlier acceleration upon the occurrence of certain exit events.
Investor Verification Checklist
- Verify the current market price of Ascendis Pharma ADS relative to the $161.52 exercise price.
- Confirm the total number of outstanding warrants and the dilution impact of the 36,390 new grants.
- Review the specific "exit events" defined in the Articles of Association that could trigger early vesting.
- Check subsequent filings for any further amendments to the Articles of Association or additional warrant grants.